Home > Boards > US Listed > Biotechs > Calithera Biosciences, Inc. (CALA)

Calithera Biosciences Announces FDA Acceptance of Investigational New

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jondoeuk Member Profile
 
Followed By 14
Posts 847
Boards Moderated 2
Alias Born 10/24/15
160x600 placeholder
Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced ... GlobeNewswire Inc. - 10/3/2019 7:05:00 AM
Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annua... GlobeNewswire Inc. - 10/1/2019 4:05:00 PM
New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab GlobeNewswire Inc. - 9/29/2019 10:30:00 AM
Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Re... GlobeNewswire Inc. - 9/28/2019 2:30:00 AM
Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Cong... GlobeNewswire Inc. - 9/26/2019 6:05:00 PM
Calithera to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/25/2019 8:05:00 AM
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019 GlobeNewswire Inc. - 9/3/2019 9:00:00 AM
Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference GlobeNewswire Inc. - 8/28/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/8/2019 4:18:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/8/2019 4:07:23 PM
Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights GlobeNewswire Inc. - 8/8/2019 4:05:00 PM
Calithera Biosciences to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019 GlobeNewswire Inc. - 8/1/2019 7:07:00 AM
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib GlobeNewswire Inc. - 7/2/2019 8:00:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/1/2019 4:08:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/27/2019 4:08:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/27/2019 4:07:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/26/2019 4:06:38 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 6/25/2019 4:50:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/21/2019 4:06:46 PM
Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares... GlobeNewswire Inc. - 6/21/2019 4:04:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 4:55:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/19/2019 4:51:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/19/2019 4:07:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/19/2019 4:06:00 PM
Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock GlobeNewswire Inc. - 6/18/2019 11:00:00 PM
jondoeuk   Monday, 07/25/16 08:56:41 AM
Re: None
Post # of 193 
Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint

SOUTH SAN FRANCISCO, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for CB-1158 for the treatment of solid tumors. CB-1158 is a first-in-class, orally available small molecule inhibitor of the enzyme arginase.

"We are pleased to be advancing the first arginase inhibitor into clinical trials. Arginase is a novel target in metabolic immuno-oncology, and these studies will allow us to assess the safety, pharmacokinetics and pharmacodynamics of this exciting new agent," said Susan M. Molineaux, Ph.D., founder, Chief Executive Officer and President of Calithera Biosciences. "CB-1158 has demonstrated significant anti-tumor activity in preclinical models, and we look forward to reporting initial clinical results with this compound in 2017.”

Arginase exerts its immunosuppressive effect by depleting the amino acid arginine in the tumor microenvironment and prevents activation and proliferation of the immune system’s cytotoxic T-cells and natural killer (NK) cells. Inhibition of arginase activity reverses this immunosuppressive block and restores T-cell function. The Phase I clinical trial will enroll patients with advanced solid tumors treated with CB-1158 as a monotherapy, as well as in combination with an anti-PD1 antibody.

http://ir.calithera.com/phoenix.zhtml?c=253557&p=irol-newsArticle&ID=2187727

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist